Vanda Pharmaceuticals Inc. VNDA
3.80 USD -0.08 (-2.06%)
Nov 5, 2026, 10:29 AM EST
3.73 Day range 3.88
3.64 52-week range 9.94
- YTD
- -56.92%
- 1 year
- -14.41%
News
prnewswire.com Vanda Pharmaceuticals Announces Participation at November 2026 Investor Conferences WASHINGTON, Nov. 3, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate at the following upcoming investor conferences in November…
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session Gainers Mesoblast (NASDAQ:MESO) stock rose 16.2% to $15.57 during Thursday's pre-market session. The market value of their outstanding shares is at $1.7 billion. Glaukos (NYSE:GKOS) stock rose 15.75%…
benzinga.com Steve Jobs' Son Says GLP-1 Weight Loss Drugs Could Be Among Most Important Medicines Ever, With Potential Impact on Cancer Reed Jobs says GLP-1 drugs could help fight cancer; Yosemite fund passes $350M target.
benzinga.com Vanda Pharma Q3 2026 Earnings Call Transcript Vanda Pharma (NASDAQ:VNDA) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.Benzinga APIs provide real-time…
benzinga.com Vanda Pharma Q3 EPS $(0.37) Beats $(0.68) Estimate, Sales $69.815M Beat $69.202M Estimate Vanda Pharma (NASDAQ:VNDA) reported quarterly losses of $(0.37) per share which beat the analyst consensus estimate of $(0.68) by 45.59 percent. This is a 2.63 percent increase over losses of $(0.38)…
benzinga.com Vanda Pharmaceuticals Targets Major GLP-1 Market Challenge with Positive Trial Outcomes Vanda Pharmaceuticals reports positive Phase 3 results for Nereus, demonstrating reduced vomiting linked to GLP-1 receptor agonist therapy.
benzinga.com Vanda Pharmaceuticals Announces Phase III Study Results Showing Significant Reduction In GLP-1 Therapy-Associated Vomiting With NEREUS NEREUS™ significantly reduced semaglutide induced vomiting including frequent multi-day and extreme vomitingKey ResultsAny vomiting (primary) 43.0% (61/142) vs 58.5% (96/164) placebo (p=0.006); 27%…
benzinga.com Vanda Pharmaceuticals Says Experimental Anxiety Treatment Misses Primary Endpoint Vanda Pharmaceuticals announced its Phase 3 trial for VQW-765 failed to meet primary endpoints for treating acute social anxiety disorder.
benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session Gainers Biodexa Pharmaceuticals (NASDAQ:BDRX) stock rose 13.3% to $0.55 during Wednesday's after-market session. Impact BioMedical (AMEX:IBO) stock rose 10.77% to $3.77. The company's market cap…- benzinga.com Vanda Pharmaceuticals' Phase III Clinical Study Of VQW-765 In Adults With Social Anxiety Disorder Did Not Meet Its Primary Endpoint; VQW-765 Was Safe And Well-Tolerated Phase III clinical study of VQW-765 in adults with social anxiety disorder did not meet its primary endpointConsistent with prior studies, VQW-765 was safe and well toleratedWASHINGTON, Oct. 14, 2026…
benzinga.com HC Wainwright & Co. Reiterates Buy on Vanda Pharmaceuticals, Maintains $20 Price Target HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Vanda Pharmaceuticals (NASDAQ:VNDA) with a Buy and maintains $20 price target.
benzinga.com Vanda Eyes First FDA-Approved Delayed Sleep-Wake Disorder Drug Vanda's Phase 3 trial of HETLIOZ for DSWPD met its primary endpoint, advancing sleep onset by 42.5 minutes. sNDA submission planned.
benzinga.com Oppenheimer Initiates Coverage On Vanda Pharmaceuticals with Outperform Rating, Announces Price Target of $10 Oppenheimer analyst Les Sulewski initiates coverage on Vanda Pharmaceuticals (NASDAQ:VNDA) with a Outperform rating and announces Price Target of $10.
benzinga.com Vanda Pharmaceuticals Receives EMA Orphan Designation For Imsidolimab For The Treatment Of Generalized Pustular Psoriasis The US Food and Drug Administration (FDA) and Japan's Ministry of Health, Labour and Welfare have previously granted Orphan Drug Designation to imsidolimab for the treatment of GPP.This marks the…- benzinga.com B. Riley Securities Reiterates Buy on Vanda Pharmaceuticals, Lowers Price Target to $12 B. Riley Securities analyst Madison El-Saadi reiterates Vanda Pharmaceuticals (NASDAQ:VNDA) with a Buy and lowers the price target from $17 to $12.
- benzinga.com HC Wainwright & Co. Maintains Buy on Vanda Pharmaceuticals, Lowers Price Target to $20 HC Wainwright & Co. analyst Raghuram Selvaraju maintains Vanda Pharmaceuticals (NASDAQ:VNDA) with a Buy and lowers the price target from $21 to $20.
- benzinga.com Vanda Pharma Q2 EPS $(1.04) Misses $(0.59) Estimate, Sales $50.529M Miss $61.925M Estimate Vanda Pharma (NASDAQ:VNDA) reported quarterly losses of $(1.04) per share which missed the analyst consensus estimate of $(0.59) by 76.27 percent. This is a 126.09 percent decrease over losses of…
benzinga.com Vanda Pharmaceuticals Affirms FY2026 Sales Guidance of $240.000M-$290.000M vs $262.154M Est Vanda Pharmaceuticals (NASDAQ:VNDA) affirms FY2026 sales outlook from $240.000 million-$290.000 million to $240.000 million-$290.000 million vs $262.154 million estimate.- benzinga.com Vanda Pharmaceuticals Announces European Medicines Agency Adopts Positive Opinion For Orphan Drug Designation Of Imsidolimab For Generalized Pustular Psoriasis This marks the first time the EMA has granted orphan drug designation recognition for a drug to treat GPP in the European Union (EU). GPP is a severe, chronic, and potentially life-threatening…
- benzinga.com Vanda Pharma Says FDA Grants Rare Pediatric Disease Designation To VCA-894A For Treatment Of Charcot-Marie-Tooth Disease, Axonal, Type 2S Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation to VCA-894A, Vanda's investigational…
- benzinga.com Vanda Pharmaceuticals Receives Japanese Orphan Drug Designation For Imsidolimab In Generalized Pustular Psoriasis Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has granted orphan drug designation to imsidolimab, a high‑affinity…
- benzinga.com HC Wainwright & Co. Maintains Buy on Vanda Pharmaceuticals, Lowers Price Target to $21 HC Wainwright & Co. analyst Raghuram Selvaraju maintains Vanda Pharmaceuticals (NASDAQ:VNDA) with a Buy and lowers the price target from $24 to $21.
benzinga.com Earnings Scheduled For May 6, 2026 - benzinga.com Vanda Pharmaceuticals' NEREUS Now Commercially Available Throughout U.S. To Prevent Vomiting Induced By Motion In Adults Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced that NEREUS™ (tradipitant) is now commercially available across the United States for the prevention of vomiting induced by motion in…
- benzinga.com Vanda Pharma Highlights Legislative Proposal Contained In FDA's FY 2027 Congressional Budget Justification; Proposal Will Eliminate Simple Statutory Requirement That FDA Must Review NDA Within 180 Days Of Filing Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today highlighted a legislative proposal contained in the FDA's FY 2027 Congressional Budget Justification.The proposal would eliminate the simple…
benzinga.com Vanda Pharmaceuticals Announces Initiation Of The Thetis Study, A Clinical Trial Of NEREUS For The Prevention Of Vomiting Induced By GLP-1 Receptor Agonists; Topline Results From Thetis Study Expected By Q4 2026; Phase 2 Study Succeeded And Met Its Primary Endpoint Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced the initiation of Thetis, a clinical trial evaluating NEREUS™ (tradipitant) for the prevention of vomiting in patients receiving…- benzinga.com Vanda Pharmaceuticals Advocates For Stronger FDA Measures To Accelerate Shift From Animal Testing To Human-Relevant Methods Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA), a leader in innovative drug development and a vocal advocate for reducing unnecessary animal testing, today voiced serious concerns over the U.S.…
benzinga.com This Equinix Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday Top Wall Street analysts changed outlook on top names. See analyst ratings page for full view. EQIX stock initiated with Outperform rating.- benzinga.com Truist Securities Initiates Coverage On Vanda Pharmaceuticals with Buy Rating, Announces Price Target of $18 Truist Securities analyst Les Sulewski initiates coverage on Vanda Pharmaceuticals (NASDAQ:VNDA) with a Buy rating and announces Price Target of $18.
benzinga.com FDA Grants Vanda Pharma's Request For Formal Evidentiary Public Hearing To Review CDER Proposal To Refuse Approval Of sNDA For HETLIOZ In Treatment Of Jet Lag Disorder Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced that the U.S. Food and Drug Administration (FDA) has granted the company's request for a formal evidentiary public hearing to review…
benzinga.com Vanda Pharmaceuticals Breaks Through With FDA Approval, Decision Date For Skin Drug Vanda stock climbs after the FDA approves Bysanti for bipolar disorder and schizophrenia and reviews rare skin disease treatment.- benzinga.com Vanda Pharmaceuticals Announces FDA Accepts Its Biologics License Application For Generalized Pustular Psoriasis Treatment Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced that the U.S. Food and Drug Administration (FDA) has accepted the filing of its Biologics License Application (BLA) for imsidolimab…
- benzinga.com FDA Accepts Vanda's New Drug Application For Rare, Life-Threatening Skin Disease Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced that the U.S. Food and Drug Administration (FDA) has accepted the filing of its Biologics License Application (BLA) for imsidolimab…
benzinga.com What's Going On With Vanda Pharma Stock Tuesday? FDA's approval of Bysanti boosts Vanda's portfolio, with potential to treat bipolar disorder, schizophrenia, and major depressive disorder.- benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session
benzinga.com ImmunityBio Posts Upbeat Q4 Earnings, Joins Arcellx, Vanda Pharmaceuticals And Other Big Stocks Moving Higher On Monday 
benzinga.com Vanda Pharmaceuticals FDA Approval Dawns A New Era For Bipolar And Schizophrenia Treatment Vanda shares rise after FDA approves Bysanti for bipolar I and schizophrenia, with launch planned for 2026.
benzinga.com Stock Market Today: Dow Jones, S&P500, Nasdaq Futures Decline After SC Strikes Down Trump's Emergency Tariffs— NVO, MSTR, VNDA In Focus (UPDATED) Editor’s Note: The future prices of benchmark tracking ETFs, the lede, the economic data, and the headline were updated in the story.- benzinga.com Market-Moving News for February 23rd VNDA: 54% | On Friday, The FDA Approved Vanda Pharmaceuticals' Bysanti (Milsaperidone) Tablets, A First Line Therapy For The Acute Treatment Of Manic Or Mixed Episodes Associated With Bipolar I…
- benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session
benzinga.com Analyst Expectations For Vanda Pharmaceuticals's Future - benzinga.com HC Wainwright & Co. Maintains Buy on Vanda Pharmaceuticals, Raises Price Target to $24 HC Wainwright & Co. analyst Raghuram Selvaraju maintains Vanda Pharmaceuticals (NASDAQ:VNDA) with a Buy and raises the price target from $22 to $24.
benzinga.com Why Vanda Pharmaceuticals Shares Are Trading Higher By Around 33%; Here Are 20 Stocks Moving Premarket 
benzinga.com Rollins Posts Downbeat Results, Joins Paycom Software, Cisco, Applovin And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session
- benzinga.com Vanda Pharmaceuticals Sees FY2026 Sales $230.000M-$260.000M vs $271.275M Est Vanda Pharmaceuticals (NASDAQ:VNDA) sees FY2026 sales of $230.000 million-$260.000 million vs $271.275 million analyst estimate.
benzinga.com Vanda Pharma Q4 EPS $(2.39) Misses $(1.32) Estimate, Sales $57.216M Miss $59.275M Estimate Vanda Pharma (NASDAQ:VNDA) reported quarterly losses of $(2.39) per share which missed the analyst consensus estimate of $(1.32) by 80.38 percent. This is a 2887.5 percent decrease over losses of…- benzinga.com Earnings Scheduled For February 11, 2026
benzinga.com Earnings Outlook For Vanda Pharma 
benzinga.com Immuneering, Phathom Pharmaceuticals, Canadian Solar And Other Big Stocks Moving Lower In Thursday's Pre-Market Session